Skip to content
DataLookout
Menu

COURAGENCT06299098

A Study to Test if Trevogrumab or Trevogrumab With Garetosmab When Taken With Semaglutide is Safe and How Well They Work in Adult Patients With Obesity for Weight Loss, Fat Loss, and Lean Mass Preservation

StatusCompleted
PhasePhase 2
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 16 versions: 16 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 14 words
    • Trial completed
    • Site details revised at 1 of 60 sites
  2. Minor Primary completion pushed from May 6, 2026 to Jun 16, 2026
    • Study completion date: Oct 30, 2026 to Oct 21, 2026
    v15
  3. Minor Primary completion date changed from estimate of May 18, 2026 to May 6, 2026v14
  4. Study Status, Referencesv13
  5. Minor Primary completion date: May 13, 2026 to May 18, 2026
    • Study completion date: Nov 4, 2026 to Oct 30, 2026
    • Secondary endpoints revised (21)
    v12
Show 10 earlier versionsHide 10 earlier versions
  1. Notable Primary endpoints: 4 to 8v11 Show 7 more changesShow less
    • Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 999 to confirmed 1005
    • Study sites: 61 to 60
    • Primary completion date: May 27, 2026 to May 13, 2026
    • Study completion date: Nov 20, 2026 to Nov 4, 2026
    • Secondary endpoints: 31 to 21
    • Study title expanded, about 3 words
  2. Notable Trial status: Active, Not Recruiting to Recruitingv10 Show 4 more changesShow less
    • Study sites: 59 to 61
    • Primary completion date: Feb 16, 2026 to May 27, 2026
    • Study completion date: Aug 17, 2026 to Nov 20, 2026
    • Secondary endpoints: 32 to 31
  3. Minor Trial status: Recruiting to Active, Not Recruiting
    • Site details revised at 59 of 59 sites
    v9
  4. Notable Enrollment target: 624 to 999v8 Show 8 more changesShow less
    • Eligibility criteria expanded, about 11 words
    • Study sites: 51 to 59
    • Primary completion date: Jun 24, 2026 to Feb 16, 2026
    • Study completion date: Jun 24, 2026 to Aug 17, 2026
    • Interventions: Garetosmab (Drug), Matching Placebo-Garetosmab (Drug), Matching Placebo-Part A (Drug), Matching Placebo-Trevogrumab (Drug), Semaglutide… to Garetosmab (Drug), Matching Placebo-Garetosmab (Drug), Matching Placebo-Part A (Drug), Matching Placebo-Trevogrumab (Drug), Semaglutide…
    • Secondary endpoints: 31 to 32
    • Study arms: 10 to 13
    • Study description expanded, about 3 words
  5. Minor Study sites: 27 to 51v7
  6. Minor Study sites: 19 to 27v6
  7. Minor Study sites: 11 to 19v5
  8. Notable Trial status: Active, Not Recruiting to Recruiting
    • Study sites: 3 to 11
    v4
  9. Minor Trial status: Recruiting to Active, Not Recruiting
    • Site details revised at 3 of 3 sites
    v3
  10. Notable Trial status: Not Yet Recruiting to Recruiting
    • Eligibility criteria expanded, about 16 words
    • Study sites: 0 to 3
    v2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Incidence of treatment-emergent adverse events (TEAEs)
Timeframe: Baseline to week 7
Severity of TEAEs
Timeframe: Baseline to week 7
Percent change in total fat mass
Timeframe: Baseline to week 26
Percent change in total lean mass
Timeframe: Baseline to week 26
Percent change in body weight
Timeframe: Baseline to week 26

Secondary (17)

Concentrations of trevogrumab in serum over time
Percent change in total fat mass
Percent change in total lean mass
Percent change in body weight
Change in waist circumference (cm)
Show 12 moreShow less
Percent change in fasting serum triglycerides
Percent change in total cholesterol
Percent change in Apolipoprotein B (Apo B)
Percent change in Low-Density Lipoprotein Cholesterol (LDL-C)
Concentrations of garetosmab in serum over time
Incidence of anti-drug antibodies (ADA) to trevogrumab after repeated doses over time
Magnitude of ADAs to trevogrumab over time
Incidence of ADAs to garetosmab after repeated doses over time
Magnitude of ADAs to garetosmab over time
Incidence of TEAEs
Severity of TEAEs
Concentration of total Growth Differentiation Factor (GDF) 8 in serum over time

Arms and interventions

PlaceboPlacebo comparator

Part A Randomized 1:1

TrevogrumabExperimental

Part A Randomized 1:1

Arm A0Experimental

Part B Semaglutide (sema) and subcutaneous (SC) placebo and intravenous (IV) placebo followed by SC placebo Randomized 1:1:1:1:1:1:1:1

Arm A1Experimental

Part B Sema and SC placebo and IV placebo followed by high dose trevogrumab (trevo) Randomized 1:1:1:1:1:1:1:1

Arm B0Experimental

Part B Sema, moderate-high dose trevo, and IV placebo followed by SC placebo Randomized 1:1:1:1:1:1:1:1

Arm B1Experimental

Part B Sema, moderate-high dose trevo, and IV placebo followed by high dose trevo Randomized 1:1:1:1:1:1:1:1

Arm C0Experimental

Part B Sema, high dose trevo, and IV placebo followed by SC placebo Randomized 1:1:1:1:1:1:1:1

Arm C1Experimental

Part B Sema, high dose trevo, and IV placebo followed by high dose trevo Randomized 1:1:1:1:1:1:1:1

Arm D0Experimental

Part B Sema, high dose trevo, and garetosmab (gareto) followed by SC placebo Randomized 1:1:1:1:1:1:1:1

Arm D1Experimental

Part B Sema, high dose trevo, and gareto followed by high dose trevo Randomized 1:1:1:1:1:1:1:1

Arm 1Experimental

Part C Sema and SC placebo Randomized 1:2:2

Arm 2Experimental

Part C Sema and SC low dose trevo Randomized 1:2:2

Arm 3Experimental

Part C Sema and SC moderate dose trevo Randomized 1:2:2

Drugs: Trevogrumab-Part A, Trevogrumab-Part B and Part C, Garetosmab, Semaglutide, Matching Placebo-Part A, Matching Placebo-Trevogrumab, Matching Placebo-Garetosmab

Sites

60 sites in 2 countries

United States 58, Puerto Rico 2